Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propofol + oxygen refers to the co-administration of the intravenous anesthetic agent propofol with supplemental oxygen, a common practice in anesthesia and critical care. Propofol is a small molecule used for induction and maintenance of general anesthesia and sedation. It acts primarily as a positive allosteric modulator of the GABA-A receptor, enhancing inhibitory neurotransmission in the central nervous system, leading to sedation, hypnosis, and amnesia[1][2][8]. Propofol also has secondary actions including inhibition of NMDA receptors and modulation of calcium influx through slow calcium ion channels[8]. Oxygen is not itself a drug but an essential medical gas administered to prevent hypoxemia during procedures requiring sedation or anesthesia. The combination does not represent a unique pharmaceutical product but rather describes standard clinical practice where propofol-induced respiratory depression necessitates supplemental oxygen administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propofol + oxygen.